{"id":3196,"date":"2026-09-15T09:32:00","date_gmt":"2026-09-15T13:32:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3196"},"modified":"2026-09-16T20:40:41","modified_gmt":"2026-09-17T00:40:41","slug":"jbi-802-shows-early-platelet-control-in-mpns","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3196","title":{"rendered":"JBI-802 Shows Early Platelet Control in MPNs"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Jubilant Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

First Clinical Disclosure (Phase I\/II)<\/p>\n

Modality<\/strong><\/p>\n

Oral Dual Small-Molecule Inhibitor (LSD1 and HDAC6)<\/p>\n

Asset<\/strong><\/p>\n

JBI-802<\/p>\n

Target<\/strong><\/p>\n

LSD1 and HDAC6<\/p>\n

Disease Area<\/strong><\/p>\n

Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis, MDS\/MPN With Thrombocytosis<\/p>\n

Summary<\/h4>\n

In the first clinical disclosure from an ongoing Phase I\/II study, oral JBI-802 produced rapid platelet-count reductions across essential thrombocythemia, polycythemia vera, myelofibrosis, and MDS\/MPN with thrombocytosis. Nine of nine evaluable ET or PV patients had reductions of 36% to 91%; all three patients at 15 mg had reductions of 72% to 81% within 30 days. The 12-patient uncontrolled dataset supports pharmacologic activity for dual LSD1 and HDAC6 inhibition, but platelet lowering alone does not establish thrombosis prevention, symptom benefit, molecular response, or disease modification.<\/p>\n

The issuer disclosure was published September 15, 2026 at 9:32 a.m. Eastern and recovered during the September 16 morning source-gap reconciliation at approximately 8:18 a.m. Eastern. As of June 30, twelve patients had received 5, 7, 15, or 20 mg. Four ET or PV patients with baseline platelets above 1,000 × 10&sup9;\/L had reductions of 30% to 75% within 30 days and maximum reductions of 72% to 91%. Responses were reported across JAK2-, CALR-, and MPL-mutated disease.<\/p>\n

No dose-limiting toxicity occurred through 15 mg. One dose-limiting thrombocytopenia event at 20 mg was managed by reducing to 10 mg, with the patient remaining on treatment. Ten of twelve reported treatment-emergent adverse events were Grade 1 or 2 and two were Grade 3 or higher; no patient discontinued for thrombocytopenia or a treatment-related event. The public dataset does not give exposure-adjusted incidence, event attribution by dose, symptom scores, spleen responses, marrow pathology, mutant-allele changes, or thrombotic outcomes.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that combined LSD1 and HDAC6 inhibition creates a controllable pharmacodynamic effect on abnormal megakaryopoiesis and platelet production. Dose-responsive reductions, activity across driver mutations, a short reported half-life, and reversibility after dose modification support that view. Against it, thrombocytopenia is also the expected on-target toxicity of suppressing platelet production, the cohort is very small, and no comparator separates drug effect from regression or concurrent care. A second interpretation is that JBI-802 may be primarily cytoreductive rather than disease modifying. The rapid platelet effect supports cytoreduction; the missing molecular, marrow, symptom, and thrombosis data prevent a stronger conclusion.<\/p>\n

Company and Product Background<\/h4>\n

Jubilant Therapeutics develops small molecules for oncology and autoimmune disease. JBI-802 is a once-daily oral dual inhibitor of LSD1, an epigenetic regulator of hematopoietic differentiation, and HDAC6, a cytoplasmic deacetylase involved in signaling, protein homeostasis, and inflammation. MPNs are clonal marrow disorders commonly driven by JAK2, CALR, or MPL mutations. Excess platelets and blood cells contribute to thrombosis, bleeding, constitutional symptoms, and progression risk.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • JBI-802 has crossed an important early threshold by showing consistent, rapid human pharmacology in thrombocytosis-predominant MPNs.<\/li>\n
  • Upgrades with:<\/strong> expansion-cohort replication, prespecified hematologic response criteria, durable symptom and spleen improvement, fewer thrombotic events, declining driver-mutation allele burden, marrow normalization, and a dose that separates control from thrombocytopenia.<\/li>\n
  • Downgrades with:<\/strong> cumulative cytopenias, bleeding, neuropathy or other HDAC6 liabilities, loss of effect after titration, or no molecular and clinical benefit beyond counts.<\/li>\n
  • Falsified if:<\/strong> adequate treatment lowers platelets without altering clonal burden, symptoms, progression, or vascular outcomes.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    JBI-802 has crossed an important early threshold by showing consistent, rapid human pharmacology in thrombocytosis-predominant MPNs. The current signal is positive but narrow: the compound lowers platelets, and dose adjustment appears feasible in this limited cohort. The clinical value depends on whether that effect converts into durable disease control without chronic cytopenic or off-target toxicity.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 — first human evidence for a dual epigenetic mechanism in MPNs. Importance:<\/strong> Positive — consistent count reductions and manageable early safety, with major efficacy gaps. Confidence:<\/strong> High on facts (patient counts, doses, laboratory changes, and dose-limiting toxicity are disclosed); moderate-low on interpretation (the cohort is uncontrolled and does not establish clinical or disease-modifying benefit).<\/p>\n","protected":false},"excerpt":{"rendered":"

    In the first clinical disclosure from an ongoing Phase I\/II study, oral JBI-802 produced rapid platelet-count reductions across essential thrombocythemia, polycythemia vera, myelofibrosis, and MDS\/MPN with thrombocytosis. Nine of nine evaluable ET or PV…<\/p>\n","protected":false},"author":1,"featured_media":3207,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[543,776,115],"class_list":["post-3196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-essential-thrombocythemia","tag-jubilant-therapeutics","tag-myeloproliferative-neoplasms"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3196"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3196\/revisions"}],"predecessor-version":[{"id":3216,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3196\/revisions\/3216"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3207"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}